We are proud to announce that Vice President of Policy Ryan Barker, was appointed as one of the 14 inaugural members of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC). The Midwest CEPAC is the newest of three public deliberative bodies convened across the country by the Institute for Clinical and Economic Review (ICER) to consider public comment and debate the findings of ICER reports on new drugs.
“The inaugural members of the Midwest CEPAC are a distinguished group of individuals, and we are proud to have them take on this critical public role. Patients, clinicians, insurers, and policymakers can all benefit from independent, clear judgments of what we know about which drugs work best for which patients. Similarly, questions of the costs of care need to be discussed with all stakeholders — including the public — at the table. The Midwest CEPAC will play a critical role in achieving these goals,” said Dr. Steven D. Pearson, ICER’s founder and president. “Bringing varied skills and perspectives to the table, the members of Midwest CEPAC will provide a unique forum within which these issues can be examined and options developed for bringing innovative drugs to those patients who can benefit from them while enhancing value for patients and the entire health system.”
Click here for the full list and bios of the Midwest CEPAC members.
